Antioxidant status in pediatric acute lymphocytic leukemia (ALL) and solid tumors: The impact of oxidative stress

Pediatric Blood and Cancer

Volumn 51, Issue 5, 2008, Pages 613-615

  Mazor, Dalia ^a   Abucoider, Abed ^b   Meyerstein, Naomi ^a   Kapelushnik, Joseph ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

ALL; Antioxidant capacity; Childhood; Solid tumors

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; CYCLOPHOSPHAMIDE; REACTIVE OXYGEN METABOLITE; THIOL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANALYTIC METHOD; ANTIOXIDANT ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLOOD LEVEL; BURKITT LYMPHOMA; CELL DEATH; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; FEMALE; FERRIC REDUCING ABILITY OF PLASMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALE; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA; SCHOOL CHILD; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL;

ADOLESCENT; ANTIOXIDANTS; CHILD; CHILD, PRESCHOOL; HUMANS; MALE; NEOPLASMS; OXIDATIVE STRESS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SULFHYDRYL COMPOUNDS;

EID: 52249084304     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21665     Document Type: Article

References (17)

1. Halliwell B. Oxidative stress and cancer: Have we moved forward? Biochem J 2007;40:1-11.
2. Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypoth 2000;55:29-35.
3. Hileman EO, Liu J, Albitar M, et al. Intrinsic oxidative stress in cancer cells: A biochemical basis for therapeutic selectivity. Cancer Chemother Phamacol 2004;53:209-219.
4. Links M, Lewis C. Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57:293-308.
5. Kennedy DD, Ladas EJ, Rheingold SR, et al. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Pediatr Blood Cancer 2005;44:378-385.
6. Neyestani TR, Fereydouni Z, Hejazi S, et al. Vitamin C status in children with acute lymphoblastic leukemia: Evidence for increased utilization. J Pediat Gastroenterol Nutr 2007;45:141-144.
7. Janaszewska A, Bartosz G. Assay of total antioxidant capacity: Comparison of four methods as applied to human blood plasma. Scand J Clin Lab Invest 2002;62:231-236.
8. Nachman J, Sather HN, Gaynon PS, et al. Augmented Berlin-Frankfurt- Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the children's cancer group. J Clin Oncol 1997;15:2222-2230.
9. Miao-Lin H. Measurement of protein thiol groups and glutathione in plasma. Meth Enzymol 1994;233:380-385.
10. Brand-Williams W, Cuvelier ME, Berst C. Use of a free radical method to evaluate antioxidant activity. LWT-Food-Sci Technol 1995;28:25-30.
11. Benzie LFF, Strain JJ. The ferric ability of plasma (FRAP) as a measure of "the antioxidant power": The FRAP assay. Analyt Biochem 1996;239:70-76.
12. Miller NJ, Rice-Evans CA, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84: 407-412.
13. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resis Upd 2004;7:97-110.
14. Murata M, Suzuki T, Midorikava K, et al. Oxidative DNA damage is induced by a hydroperoxide derivative of cyclophosphamide. Free Radic Biol Med 2006;217:71-75.
15. Wagnerr T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 1994;26:439-456.
16. Shaw IC, Graham MI. Mesna - A short review. Cancer Treat Rev 1987;14:67-86.
17. Kong Q, Lillehei KO. Antioxidant inhibitors for cancer therapy. Med Hypoth 1998;51:405-409.